- Home
- MTLS vs TNGX Comparison
MTLS vs TNGX Comparison
Compare MTLS & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTLS
- TNGX
- Stock Information
- Founded
- MTLS 1990
- TNGX 2014
- Country
- MTLS Belgium
- TNGX United States
- Employees
- MTLS N/A
- TNGX N/A
- Industry
- MTLS Computer Software: Prepackaged Software
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- MTLS Technology
- TNGX Health Care
- Exchange
- MTLS Nasdaq
- TNGX Nasdaq
- Market Cap
- MTLS N/A
- TNGX 317.4M
- IPO Year
- MTLS 2014
- TNGX N/A
- Fundamental
- Price
- MTLS $4.79
- TNGX $1.28
- Analyst Decision
- MTLS Buy
- TNGX Strong Buy
- Analyst Count
- MTLS 1
- TNGX 7
- Target Price
- MTLS $9.50
- TNGX $12.33
- AVG Volume (30 Days)
- MTLS 201.3K
- TNGX 789.6K
- Earning Date
- MTLS 04-24-2025
- TNGX 05-07-2025
- Dividend Yield
- MTLS N/A
- TNGX N/A
- EPS Growth
- MTLS 106.79
- TNGX N/A
- EPS
- MTLS 0.24
- TNGX N/A
- Revenue
- MTLS $276,182,835.00
- TNGX $42,069,000.00
- Revenue This Year
- MTLS $6.55
- TNGX N/A
- Revenue Next Year
- MTLS $9.21
- TNGX N/A
- P/E Ratio
- MTLS $20.89
- TNGX N/A
- Revenue Growth
- MTLS 4.15
- TNGX 15.17
- 52 Week Low
- MTLS $4.70
- TNGX $1.24
- 52 Week High
- MTLS $9.69
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- MTLS 31.61
- TNGX 24.31
- Support Level
- MTLS $4.81
- TNGX $1.48
- Resistance Level
- MTLS $5.25
- TNGX $1.66
- Average True Range (ATR)
- MTLS 0.16
- TNGX 0.16
- MACD
- MTLS 0.08
- TNGX -0.02
- Stochastic Oscillator
- MTLS 13.85
- TNGX 5.00
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.